

Sanofi
Form 6-K
July 28, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2011

Commission File Number: 001-31368

SANOFI

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____

In July 2011, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 to 99.5 which are incorporated herein by reference.

Exhibit List

| <u>Exhibit No.</u> | <u>Description</u> |
|--------------------|---|
| Exhibit 99.1 | Press release dated July 28, 2011: Half Year Results Announcement |
| Exhibit 99.2 | Press release dated July 28, 2011: Genzyme Product Supply Update |
| Exhibit 99.3 | Genzyme Product Sales Statement, for the Product Sales Measuring Period ended June 30, 2011 |
| Exhibit 99.4 | Press release dated July 28, 2011: Dr. David-Alexandre Gros appointed Chief Strategy Officer of Sanofi |
| Exhibit 99.5 | Press release dated July 12, 2011: Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 28, 2011

SANOFI

By /S/ John Felitti
Name: John Felitti
Title: Associate Vice President,
Corporate Law, Financial &
Securities Law

Exhibit Index

| <u>Exhibit No.</u> | <u>Description</u> |
|--------------------|---|
| Exhibit 99.1 | Press release dated July 28, 2011: Half Year Results Announcement |
| Exhibit 99.2 | Press release dated July 28, 2011: Genzyme Product Supply Update |
| Exhibit 99.3 | Genzyme Product Sales Statement, for the Product Sales Measuring Period ended June 30, 2011 |
| Exhibit 99.4 | Press release dated July 28, 2011: Dr. David-Alexandre Gros appointed Chief Strategy Officer of Sanofi |
| Exhibit 99.5 | Press release dated July 12, 2011: Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis |